Key points
- The Advisory Committee on Immunization Practices (ACIP) develops recommendations on how to use vaccines to control disease in the United States.
- These recommendations become official ÐÇ¿ÕÓéÀÖ¹ÙÍø policy once adopted by ÐÇ¿ÕÓéÀÖ¹ÙÍø's Director.
- Learn about current and historical ACIP recommendations for COVID-19 vaccine.
Published in Morbidity and Mortality Weekly Report (MMWR)
The Advisory Committee on Immunization Practices (ACIP) provides advice and guidance to the Director of the ÐÇ¿ÕÓéÀÖ¹ÙÍø regarding use of vaccines and related agents for control of vaccine-preventable diseases in the civilian population of the United States. Recommendations made by the ACIP are reviewed by the ÐÇ¿ÕÓéÀÖ¹ÙÍø Director and, if adopted, are published as official ÐÇ¿ÕÓéÀÖ¹ÙÍø/HHS recommendations in the Morbidity and Mortality Weekly Report (MMWR).
CURRENT COVID-19 Vaccine Recommendations
MMWR, December 12, 2024. Vol 73 (49); 1118-1123
Use of Additional Doses of 2024–2025 COVID-19 Vaccine for Adults Aged ≥65 Years and Persons Aged ≥6 Months with Moderate or Severe Immunocompromise: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Print version
MMWR, September 10, 2024. Vol 73 (37);819-824
Use of COVID-19 Vaccines for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–2025.
Print version
ARCHIVED COVID-19 Immunization Publications
For your convenience, these archived publications can be used for historical and research purposes.
MMWR, April 25, 2024, Vol 73(16);377-381
Use of an Additional Updated 2023–2024 COVID-19 Vaccine Dose for Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024
Print version
MMWR, October 20, 2023, Vol 72(42);1140–1146
Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023
Print version
MMWR, June 16, 2023, Vol 72(24);657–662
Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023
Print version
MMWR, November 11, 2022, Vol 71(45); 1436-1441
Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022 | MMWR (cdc.gov)
Print version
MMWR, August 4, 2022, Vol 71(31); 988-992
Interim Recommendation of the Advisory Committee on Immunization Practices for use of the Novavax COVID-19 vaccine in persons aged 18 years and older— United States, July 2022
Print version
MMWR, June 28, 2022, Vol 71(26);859–868
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months–5 Years — United States, June 2022
Print version
MMWR, March 18, 2022, Vol 71(11);416–421
Use of Moderna COVID-19 Vaccine in Persons Aged ≥18 Years and Considerations for Extended Intervals for Administration of Primary Series Doses of mRNA COVID-19 Vaccines — United States, February 2022
Print version
MMWR, January 21, 2022, Vol 71(3);90–95
Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices – United States, December 2021
Print version
MMWR, November 5, 2021, Vol 70(45);1579–1583
Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years — United States, November 2021
Print version
MMWR, November 5, 2021, Vol 70(44);1545–1552
Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines — United States, 2021
Print version
MMWR, September 24, 2021, Vol 70(38);1344–1348
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
Print version
MMWR, August 13, 2021, Vol 70(32);1094-1099
Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021
Print version
MMWR, July 9, 2021, Vol 70(27);977–982
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
Print version
MMWR, May 14, 2021, Vol 70(20);749–752
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12–15 Years — United States, May 2021
Print version
MMWR, April 30, 2021, Vol 70(17);651-656
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
Print version
MMWR, March 2, 2021, Vol 70(9);329–332
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine — United States, February 2021
Print version
MMWR, December 22, 2020, Vol 69(5152);1657-1660
The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020
Print version
MMWR, December 20, 2020, Vol 69(5152);1653-1656
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020
Print version
MMWR, December 13, 2020, Vol 69(50);1922-1924
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020
Print version
MMWR, December 3, 2020, Vol 69(49);1857-1859
The Advisory Committee on Immunization Practices' Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine — United States, 2020
Print version